Singh will lead Juniper Biologics operations from Singapore and deliver medicines in oncology, Rare/Orphan Diseases and gene therapy
Singapore-headquartered Juniper Biologics, a science-led healthcare company focusing on researching, developing and commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.
Juniper Biologics will be focused on researching, developing and commercialising innovative medications in the areas of oncology, Rare/Orphan Diseases and gene therapy. The company is headquartered in Singapore.
”The opportunity to lead Juniper Biologics is one I could not pass up. There is a tremendous global need for effective therapies and preventions for oncology, Rare/Orphan Diseases and gene therapy. Success would mean alleviation of a lot of human suffering,” said Raman Singh, CEO, Juniper Biologics.
Singh brings over 25 years of experience from the pharmaceutical industry, most recently as CEO of Mundipharma for its Pharmaceutical & Consumer Business where he grew the operations of the emerging market from $45 million to close to $1 billion in eight years.
Before joining Mundipharma, Singh served as Vice-President of commercial operations for emerging markets at GSK. In his role, he oversaw all aspects of the brand’s commercial operations across its emerging markets. Singh previously held positions at Abbott as the regional director in Australia and New Zealand, and General Manager for Korea, as well as various sales, marketing and strategy positions at Bayer.
More recently during the COVID-19 pandemic, Singh spearheaded R&D efforts to investigate how Mundipharma’s consumer products could help the developing and developed world impacted by the pandemic, manage the spread of the virus. Laboratory tests with Duke-NUS and other labs worldwide were initiated to determine the efficacy of certain Betadine products against the spread of the COVID-19 virus.
Singh’s support of Singapore as a strong global business hub has been highlighted across international print and broadcast media. He was also featured as a brand ambassador in the Singapore Tourism Board and Economic Development Board’s POSSIBLE global brand campaign in 2017.
Mr Singh’s many accolades include being named among the Most Powerful People in Healthcare from 2015-2019 by Medicine Maker, Executive of the Year 2017-2019 by SBR Management Excellence Awards and Executive of the Year 2018 at the Scrip Awards.
Singh also sits on the board for Liquidia, a late-stage clinical biopharmaceutical company focused on the development and commercialisation of novel products. He is the only non-US-based Board Member. During his term, he successfully oversaw the IPO in NASDAQ in 2016 as well as the acquisition of RareGen, a portfolio company of PBM Capital Group. A champion of digital healthcare, Mr Singh also sits on the boards of Biofourmis Healthcare and Neuroglee Therapeutics.
On his appointment at Juniper Biologics, Singh added “There is a great unmet need in the treatment of oncology, Rare/Orphan Diseases and gene therapy and it is our responsibility as a company to provide patients with easier access to therapeutic strategies to improve the quality of their lives. Our mission at Juniper Biologics reinforces the drive to deliver new possibilities in treatments, focusing on the best interest of patients and those who care for them.”
